Evidence map›Paper›PMID 34626752›Full record

ReviewFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2021

The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products.

Jinpeng Li, Ricardo Carvajal, Leon Bruner, Norbert E Kaminski

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Prevalence of cannabidiol use and correlates in U.S. adults.Drug and alcohol dependence reports · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jinpeng LiCenter for Research on Ingredient Safety, Michigan State University, East Lansing, MI, 48824, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, 48824, USA.
Ricardo CarvajalHyman, Phelps & McNamara, P.C., Washington, D.C, 20005, USA.
Leon BrunerInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, 48824, USA.
Norbert E KaminskiCenter for Research on Ingredient Safety, Michigan State University, East Lansing, MI, 48824, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, 48824, USA; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, 48824, USA. Electronic address: kamins11@msu.edu.
Michigan State University · USPhelps Hospital · US

Funding

Cannabinoids Modulate Immune Cell-provoked Astrocyte Functions to Suppress HIV-Associated Neuroinflammatory ResponsesR01DA047180 · NIDA · MICHIGAN STATE UNIVERSITY · PI KAMINSKI, NORBERT E · 2018 to 2023
$2.4M
NIDA NIH HHS R01 DA047180
6 · The paper itself

Abstract

The popularity of cannabidiol (CBD) in consumer products is soaring as consumers are using CBD for general health and well-being as well as to seek relief from ailments especially pain, inflammation, anxiety, depression, and sleep disorders. However, there are limited data currently in the public domain that provide support for these benefits. By contrast, a significant amount of safety evaluation data for CBD have been obtained recently from pre-clinical and clinical studies of the CBD therapeutic Epidiolex®. Yet some key data gaps concerning the safe use of CBD still remain. Furthermore, current regulations on CBD use in consumer products remain uncertain and often conflict between the state and federal level. In light of the rapidly expanding popularity of CBD-related products in the marketplace, here we review the current understanding of the benefits, safety, and regulations surrounding CBD in consumer products. This review does not advocate for or against the use of CBD in consumer products. Rather this review seeks to assess the state-of-the-science on the health effects and safety of CBD, to identify critical knowledge gaps for future studies, and to raise the awareness of the current regulations that govern CBD use in consumer products.

Indexed as

Consumer Product SafetyDrug and Narcotic ControlCannabidiolHumansCannabidiolCannabidiolCannabinoidCBD regulationsConsumer productsHempIngredient safety

Identifiers

PMID34626752
PMCPMC9028607
OpenAlexW3203471730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.